Creative Biolabs is one of the leading custom antibody generation and development providers. We specialize in the generation of antibodies against a wide range of targets for R&D, diagnostic, and therapeutic applications. Currently, we have launched a series of in vitro diagnostic (IVD) antibody development services targeting numerous diagnostic biomarkers of human diseases. Here, we focus on the IL-13 as a marker of sepsis.

IL-13

IL13 gene encodes a protein in humans, termed interleukin 13 (IL-13) with a mass of 13 kDa and folding into 4 alpha helical bundles. IL-13 is an anti-inflammatory cytokine that reduces inflammatory cytokine production and enhances monocyte survival and MHC class II and CD23 expression. The only report of IL-13 in human sepsis noted no increase in IL-13 concentration, in contrast to animal data. This study further examined the expression of IL-13 in relation to human sepsis.

Postulated pathway of IL-13. Fig.1. Postulated pathway of IL-13. (Vatrella A., 2014)

The Role of IL-13 in Sepsis

IL-13 is an important cytokine in allergic inflammation and disease. Many cell types, especially Th2 cells, secret IL-13. IL-13 and IL-4 have a common cellular receptor, IL-4 type 1 receptor. Thus, IL-13 and IL-4 have many similarities in anti-inflammatory responses. IL-13 reduces the expression of TNF-α, IL-1, IL-8, and MIP-1α in monocytes. IL-13 also inhibits the production of TNF-α, IFN-γ, and IL-12 and thus improves LPS-induced lethality in animal models, suggesting that IL-13 may play a role in sepsis. It has been reported that the intestinal concentration of IL-13 was dramatically increased in rats with sepsis as compared with healthy normal rats. However, IL-13 was not detected in plasma in patients with sepsis and increased IL-13 production was not found to take part in an inducible host defense mechanism during sepsis. Further studies will be necessary to elucidate the role of IL-13 in sepsis.

Immunohistochemistry for IL-13. Fig.2. Immunohistochemistry for IL-13. (Matsukawa A., 2000)

IVD Antibody Development Services Targeting IL-13 Marker

Based on the rapid development of IVD technology and novel biomarkers, IVD antibodies are extensively used for disease screening and therapeutic monitoring. Diverse immunoassays are applied, including lateral flow assay, immunochemistry, sandwich ELISA, etc. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to deliver high-quality IVD antibody development services targeting numerous biomarkers of sepsis, such as IL-13. With years of devotion and accumulation in this particular field, Creative Biolabs is confident in offering you the best products and services.

For more detailed information, please feel free to contact us or directly send us an inquiry.

References

  1. Vatrella A., (2014) “Dupilumab: a novel treatment for asthma.” Journal of asthma and allergy, 25(3): 123-130.
  2. Matsukawa A., (2000) “Expression and contribution of endogenous IL-13 in an experimental model of sepsis.” The Journal of Immunology, 164: 2738-2744.

For Research Use Only.


Related Services:

Online Inquiry
Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
Contact Us USA

Tel:
Fax:
Email:
UK

Tel:
Email:

Germany

Tel:
Email:

Follow us on:
Copyright © 2024 Creative Biolabs.
Inquiry Basket